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Abstract
Background: Our previous publication showed that 9% of patients with a history of myocardial
infarction MI. could be labeled as aspirin resistant; all of these patients were aspirin resistant
because of non-compliance. This report compares the relative frequency of aspirin resistance
between known compliant and non-compliance subjects to demonstrate that non-compliance is the
predominant cause of aspirin resistance.
Methods: The difference in the slopes of the platelet prostaglandin agonist (PPA) light aggregation
curves off aspirin and 2 hours after observed aspirin ingestion was defined as net aspirin inhibition.
Results:  After supposedly refraining from aspirin for 7 days, 46 subjects were judged non-
compliant with the protocol. Of the remaining 184 compliant subjects 39 were normals and 145
had a past history of MI. In known compliant subjects there was no difference in net aspirin
inhibition between normal and MI subjects. Net aspirin inhibition in known compliant patients was
statistically normally distributed. Only 3% of compliant subjects (2 normals and 5 MI) had a net
aspirin inhibitory response of less than one standard deviation which could qualify as a conservative
designation of aspirin resistance. A maximum of 35% of the 191 post MI subjects could be classified
as aspirin resistant and/or non-compliant: 9% aspirin resistant because of non-compliance, 23%
non-compliant with the protocol and possibly 3% because of a decreased net aspirin inhibitory
response in known compliant patients.
Conclusion: Our data supports the thesis that the predominant cause of aspirin resistance is
noncompliance.
Background
A daily aspirin delays the progression of occlusive athero-
sclerotic vascular disease [1-5]. Patients with a history of
myocardial infarction who are taking aspirin have a 25%
decrease in adverse vascular events while patients with
increasing symptoms of angina have a 50% decrease in
vaso-occlusive events with aspirin therapy [6-8]. However,
the rapid progression of symptomatic occlusion in some
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patients prescribed aspirin has led to the notion that these
patients are resistant to the effects of aspirin.
Aspirin resistance has been loosely defined as decreased
inhibition of platelets when measured using a platelet
function assay or by quantitation of a serum or urinary
metabolite of thromboxane B2 and has been described in
up 45% of patients [9-12]. The proportion of patients
who fit a particular author's definition of aspirin resist-
ance varies according to the method used to assess aspi-
rin's antiplatelet effect as well as the somewhat arbitrary
separation of patients into subsets of aspirin resistant and
aspirin sensitive patients [13]. Five studies and two meta-
analysis show that patients with, "aspirin resistance", have
a more rapid progression of their atherosclerotic disease
[14-20].
Clinically important causes of aspirin resistance are non-
compliance and non-aspirin non-steroidal anti-inflam-
matory drugs (NANSAIDs) interference with aspirin's
effect and other hypothesized mechanisms like increased
platelet turnover [21-23]. We have previously reported
that approximately 9% of MI subjects who were presumed
to be aspirin resistant were aspirin resistant because of
noncompliance [24]. Compliance was documented as a
key factor in explaining decreased platelet inhibition with
aspirin in five other reports (Table 1) [25-29]. In order to
properly treat a patient who appears to be aspirin resistant
it is important for a clinician to have some estimate as to
the likely cause.
We evaluated our aspirin platelet function data to deter-
mine what proportion of subjects could be classified as
non-compliant and what percentage of subjects could be
classified as aspirin resistant from a cause that was inde-
pendent of compliance [30]. Compliance with both off
aspirin and 2 hour post aspirin was confirmed with ara-
chidonic acid (AA) light aggregometry. The protocol
required patients to stop aspirin and NANSAIDs for 7
days. Compliance was assured by watching the subjects
ingest aspirin and by demonstrating diminished post
aspirin AA stimulated platelet aggregation. The degree of
aspirin induced inhibition of platelet function was
assessed using platelet prostaglandin agonist (PPA) stim-
ulated light aggregations measured when subjects were off
aspirin and 2 hours after observed aspirin ingestion [31].
The decrease in aspirin induced platelet response was used
to calculate a novel measurement of aspirin effect, net
aspirin inhibition. The presented data support the thesis
that the predominant cause of aspirin resistance is non-
compliance [32].
Methods
Subjects were contacted by phone, and after a detailed
explanation of the study were invited to participate. Prior
to the study informed consent was obtained. Inclusion
criteria for the MI. patients were hospital admission for a
myocardial infarction during the period between 1995
and 2000 and having been prescribed aspirin for at least
of one month prior to study. Exclusion criteria were: his-
tory of aspirin noncompliance; primary care physician
determination that the patient may not be withdrawn
from aspirin; history of hemorrhagic cerebral vascular
accident; coronary arteritis; thrombocytopenia; known
hypercoagulable disorders; use of non-aspirin nonsteroi-
dal anti-inflammatory drugs (NANSAIDs) or cyclooxyge-
nase (COX)-2 inhibitors during the seven days prior to
blood draw; uremia/dialysis or a creatinine greater than
3.0 mg/dl; and failure to provide written informed con-
sent. In addition, thirty nine normal subjects who had not
taken platelet inhibiting drugs for seven days and had no
known vascular or renal disease were studied. Their meas-
urements of platelet response were compared with those
obtained from the myocardial infarction patients. Of the
350 subjects who met the study criteria, 250 agreed to par-
ticipate and 230 completed the study. Of the 230 subjects
45 were excluded from the analysis of compliant subjects
because their off aspirin aggregation responses to AA were
less than 50% of maximal and one patient who admitted
to violating the protocol's stipulation not to take NAN-
SAIDs. These subjects were judged not to be compliant
with the protocol's instructions to refrain from ingesting
aspirin or NANSAIDs for 7 days. The 184 subjects (39 nor-
mals and 145 post myocardial infarction) who were com-
pliant with the protocol were studied as known compliant
subjects. The total number of compliant and noncompli-
Table 1: Demonstration of Aspirin non-Compliance by Repeat Testing
Methods for
N % non-Compliant ASA Effect Repeat Testing for Compliance After Reference
192 9.0 AA Light Aggregometry Observed ASA ingestion [24]
212 14.0 PFA-100 Strict reinforcement of compliance [27]
203 3.4 Thromboelastography Hospitalization [26]
73 16.0 Thromboxane B2: plasma Admitted to non-compliance [28]
87 20.0 Collagen Light Aggregometry Admitted to non-compliance [29]
678 2.0 AA light Aggregometry Ex vivo ASA [25]Journal of Translational Medicine 2008, 6:46 http://www.translational-medicine.com/content/6/1/46
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ant post-MI patients was 191. This study was approved by
the Institutional Review Boards at McLaren Medical
Center, Flint, MI. and at Ingham Regional Medical Center,
Lansing, MI. and was carried out according to the princi-
ples of the Declaration of Helsinki.
Light transmittance aggregometry
Platelet function was measured using light transmittance
aggregometry at 2 time points: after stopping aspirin for 7
days (off aspirin); and 2 hours after observed aspirin
ingestion (on aspirin). Subjects were instructed to with-
hold all antiplatelet agents for a period of 7 days. Blood
was drawn (off aspirin) for platelet aggregations and the
subjects were then instructed to ingest a 325 mg aspirin
tablet while the nurse watched. Two hours after the
observed ingestion of aspirin (on aspirin) aggregation was
assessed for the second time.
Using a 21 g butterfly a minimum of 5 ml of whole blood
was drawn by venipuncture into a separate syringe before
an additional 9 ml of whole blood was collected using a
10 ml plastic syringe containing 1 ml of 3.2% sodium cit-
rate.
Platelet counts were performed using a Coulter AcT,
Miami, Fl. Whole blood was centrifuged 200 × g for 10
minutes for platelet-rich plasma and 2000 × g for 15 min-
utes for platelet poor plasma.
Light transmittance aggregometry was performed in
duplicate using a Helena PACKS4 aggregometer, Beau-
mont, Tx. The final platelet concentration was adjusted
with platelet poor plasma to 150,000/μL. Agreement
between the duplicate aggregation curves yielded an intra-
class correlation coefficient (ICC) of r = 0.99. (The ICC is
a reliability statistic that reflects the extent to which two
measurements agree.) To assess the amount of aspirin
induced inhibition of platelet function we used the slope
of the PPA (30 μM Analytical Control Systems, Fishers,
In.) stimulated light aggregometry curve [31]. We defined
net aspirin inhibition as the difference between the PPA
slopes off and on aspirin. Thus, it was important to know
whether the subjects had complied with the protocol's
dictum not to take aspirin for 7 days. Light transmittance
aggregation with AA (1.0 mM Chronolog, Havertown,
Pa.) was used to determine if subjects had refrained from
aspirin ingestion for 7 days. AA aggregations were evalu-
ated as percent of maximal aggregation. Normal, non-
aspirin exposed, platelets aggregate. While on aspirin
platelets exhibit minimal AA aggregation (Figure 1) [31].
In this study subjects with less than 50% of maximal AA
stimulated platelet aggregation were judged to be aspirin
inhibited. Our prior publication showed that the 50%
aggregation delimiter visually separated patients into two
groups, normal and aspirin inhibited [24].
Statistical Analysis
A general linear model was used to evaluate the relation-
ship between the off aspirin PPA slope and the difference
between the off and on aspirin PPA slopes. The patient
with the largest net aspirin inhibitory response was deter-
mined to be an outlier using the Grubbs test for outlying
points and was removed from the analysis for normal dis-
tribution [33]. The Kolmogorov-Smirnov test was used to
determine if the data were normally distributed. Statistical
significance was set at a p value of 0.05 or less. All statisti-
cal analysis was performed by Alpha Biostats, Reno NV.
using SPSS software, Chicago, Il.
The authors had full access to the data and take responsi-
bility for its integrity. All authors have read and agreed to
the manuscript as written.
Note that PPA demonstrates a gradual return of platelet  aggregation to normal over 3 days Figure 1
Note that PPA demonstrates a gradual return of 
platelet aggregation to normal over 3 days. This char-
acteristic of PPA stimulated aggregation makes it useful for 
measuring gradations of aspirin induced platelet inhibition. 
AA aggregation remains unresponsive for 3 days and returns 
to normal function between days 3 and 4. AA stimulated 
platelet aggregations were used to show if aspirin platelet 
inhibition was present or absent [31].
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Results
Compliant Subjects
The mean age for the 184 known compliant subjects was
63 ± 11 years, with 63% males and 37% females. The
mean BMI for myocardial infarction patients was 29.4
with 39 percent having a BMI of more than 31. Thirty nine
percent of the coronary artery disease patients had two or
more documented myocardial infarctions. The percent of
patients with additional risk factors for atherosclerotic
vascular disease is presented in Table 2.
All known compliant subjects had a greater than 50%
decrease in aggregation response to AA two hours after
observed aspirin ingestion. For these compliant subjects
the mean off aspirin PPA aggregation curve slope was 57
± 14. The mean on aspirin PPA aggregation slope was 15
± 14. The mean difference between the PPA aggregation
slopes off and on aspirin represents net aspirin inhibition
and was 42 ± 16. Net aspirin inhibition demonstrated a
normal distribution curve (Figure 2). No difference was
observed between the 39 normal subjects and the 145
myocardial infarction patients for PPA aggregation slopes
off and on aspirin or for net aspirin inhibition (p = 0.61).
Decreased aspirin response could be defined using the cal-
culated standard deviation. For example, if a decreased
aspirin response is defined as the difference in PPA slope
between off and on aspirin of one standard deviation or
less, 16, then of the 184 compliant subjects 7 (3%) would
be classified as having a decreased aspirin response (Fig-
ure 3). Of these 7 subjects 5 of 145 (3.4%) had prior myo-
cardial infarctions and 2 of 39 were normal subjects.
The amount of platelet inhibition by aspirin in compliant
subjects was related to the off aspirin response (figure 3).
As the slope of the off aspirin PPA stimulated aggregation
curve increased, net aspirin inhibition increased. Even
though net aspirin inhibition was proportional to the off
aspirin PPA slope, those subjects with a one standard devi-
ation or less decrease in net aspirin inhibitory response
could not be identified by just using their PPA response
off aspirin.
Non-compliant subjects
The mean age for the 191 post MI patients was 61 ± 13
with 66% males and 34% females. As previously reported
16 post-MI patients evaluated after having been pre-
scribed a daily aspirin for at least one month had normal
AA light aggregations. However, 2 hours after observed
ingestion of 325 mg of aspirin AA aggregations were
blocked demonstrating that non-compliance was the
cause of the initial non-response to aspirin [24]. An addi-
tional 45 patients were judged to be non-compliant with
the protocol's stipulation that they stop taking aspirin for
seven days because on the 7th day of their proscribed absti-
nence from aspirin their AA aggregations demonstrated
aspirin inhibition. One patient violated the protocol's
stipulation not to take NANSAIDs. Of the 191 post-MI
patients 62 (32%) were either non-compliant with their
prescribed daily aspirin or with the protocols dictum of
stopping aspirin and NANSAIDS for 7 days (Table 3).
Discussion
After assuring compliance by observing post MI and nor-
mal subjects taking their aspirin, we determined that only
Table 2: MI Patient Clinical Measures
Mean Age 63 ± 11 years
Mean BMI 29.4 ± 5.6
BMI > 31 39%
Two or More Mis 33%
Smokers 39%
Diabetes 29%
Hypertension (≥ 140/≥ 90) 52%
Total Cholesterol >200 28%
Total Cholesterol >240 6%
HDL < 40 50%
LDL > 130 31%
LDL > 159 9%
NOTES:
Clinical measures were not available for the control subjects.
Not all MI patients have complete clinical measures data.
When the single point with the largest aspirin response is  removed as a statistical outlier, the net aspirin inhibitory  response distribution curve is judged to be normally distrib- uted Figure 2
When the single point with the largest aspirin 
response is removed as a statistical outlier, the net 
aspirin inhibitory response distribution curve is 
judged to be normally distributed.Journal of Translational Medicine 2008, 6:46 http://www.translational-medicine.com/content/6/1/46
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7 of 184 (3%) demonstrated decreased platelet inhibition
that could be defined as aspirin resistance. There was no
difference in net aspirin inhibitory response between nor-
mal adults and myocardial infarction patients. This sug-
gests that MI patients who are stable enough to participate
in a week-long out patient study have a response to aspi-
rin that is similar to normal subjects.
We used a novel parameter, net aspirin inhibition, to
measure the degree of platelet inhibition produced by
aspirin. The differences in PPA aggregrometry slopes off
and on aspirin demonstrated a normal distribution sug-
gesting that people possibly classified as aspirin resistant
in this study were not a distinct population, but represent
the lower portion of the bell shaped curve (Figure 2).
Because net aspirin inhibition is a continuous variable we
thought that designating those subjects with less than a
one standard deviation decrease in net aspirin inhibitory
response as possibly aspirin resistant seemed reasonable.
However, separating aspirin sensitive from aspirin resist-
ant subjects is an arbitrary designation. Perhaps a more
clinically useful separation could be derived from a pro-
spective study evaluating net aspirin inhibition as a pre-
dictor of future vascular events.
Net aspirin inhibition was related to the off aspirin
response (Figure 3). Because aspirin specifically and irre-
versibly blocks the platelet enzyme cyclooxygenase-1
(COX-1), the variation in observed aspirin inhibition may
reflect individual differences in the resting platelet's
dependence on activation via the arachidonic acid path-
way [31,34,35]. It may be that the subset of subjects with
a decreased net aspirin inhibition are those who might
benefit from an additional inhibitor of platelet function.
This hypothesis needs to be tested in a future study. The
information obtained from known compliant subjects
confirms that platelet inhibitory response to aspirin is var-
iable, but that a clearly delimited subset of people with a
markedly decreased aspirin platelet inhibitory response
cannot be defined.
Current clinical considerations for aspirin resistance
include patients who are non-compliant, have NANSAID
interference with aspirin's ability to inhibit platelets or
have a decreased aspirin response. Taken together with
our prior report our post MI population of 191 patients
had 16 subjects who were noncompliant while taking
their daily aspirin another 46 subjects who were non-
compliant with the protocol stipulation that they refrain
from aspirin ingestion for 7 days and 1 patient who vio-
lated the protocols stipulation not to take NANSAIDs
[24]. If the above noncompliant subjects are removed
The seven subjects with less than 1 standard deviation  decrease in their on aspirin slopes are depicted by open  squares ( ), those with a decrease in PPA slope between 1  and 2 standard deviations by solid diamonds ( ) and those  with a greater than 3 standard deviation decrease by open  circles (m) Figure 3
The seven subjects with less than 1 standard devia-
tion decrease in their on aspirin slopes are depicted 
by open squares (h), those with a decrease in PPA 
slope between 1 and 2 standard deviations by solid 
diamonds (r) and those with a greater than 3 stand-
ard deviation decrease by open circles (m). A direct 
relationship is observed between PPA slope off aspirin and 
the net aspirin inhibitory response. (p < 0.001).
Table 3: Post MI Subjects with Aberrant Platelet Response to Aspirin
# of subjects
Non-Compliant
1. Prescribed daily aspirin 16
2. Protocol directive not to take Aspirin for 7 days 45
3. Protocol directive not to take NANSAIDs for 7 days 1
Protocol Compliant
<1 S.D. decrease in Net Aspirin Inhibition 5
Total 67
93% (62 of 67) of aberrant platelet responses to aspirin were due to non-compliance. Among compliant post MI subjects 3% may be classified as 
aspirin resistant.Journal of Translational Medicine 2008, 6:46 http://www.translational-medicine.com/content/6/1/46
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from the analysis only 5 known compliant post MI sub-
jects could be identified as having a decreased aspirin
effect that could be labeled as aspirin resistant. Of the 67
post MI subjects with an aberrant aspirin effect on plate-
lets 62 (93%) were because of non-compliance with either
their prescribed daily aspirin or with the protocol's direc-
tion not to take aspirin or an NANSAID for 7 days (Table
2).
Poor platelet inhibition by aspirin is associated with an
increase in rate of occlusive atherosclerotic disease [14-
18]. A meta-analysis confirmed the increased risk of occlu-
sive vascular disease in patients classified as aspirin resist-
ant [19]. In this meta-analysis the risk for vascular disease
was not decreased in those patients who were prescribed
Plavix to treat their aspirin resistance. Our data supports
the thesis that most of the aspirin resistant patients are
resistant because of non-compliance. Perhaps Plavix's lack
of benefit in aspirin resistant patients is also because of
non-compliance.
Compliance in 1521 myocardial infarction patients was
investigated by asking patients to list their medications
[36]. Patients who discontinued their daily aspirin one
month after their myocardial infarction had a lower sur-
vival rate at one year compared to compliant patients 91%
vs 97%, p < 0.001 [36]. Strict enforcement of compliance
can improve the percentages of patients whose platelets
are appropriately inhibited by aspirin [27]. These data
suggest that discovering which patient has a problem with
compliance could improve the health of patients with
CAD.
Conclusion
Aspirin resistance is an unfortunate descriptor. It suggests
an inherited or acquired defect for the ability of aspirin to
acetylate platelet COX-1. Our current data interpreted in
the context of our prior publication as well as several
recent reviews reinforces the importance of patient com-
pliance as a cause of poor inhibition of platelets or aspirin
resistance [24,37,32,38,39]. In view of these findings we
suggest that a more accurate nomenclature for patients
with poor platelet inhibition by aspirin might rely on the
etiology of the poor aspirin response and would accom-
modate non-compliance, drug interactions and other pos-
sible causes.
Platelet stimulation with AA easily stratifies patients as
compliant or noncompliant while PPA stimulated
aggregometry allows identification of patients whose
platelets demonstrate decreased inhibition with aspirin.
For the clinician who is confronted with a patient with
increasing CAD symptoms the question of aspirin resist-
ance because of compliance or interference with NAN-
SAIDs or decreased aspirin response represents a problem.
If the patient is concurrently taking both aspirin and an
NANSAID then the appropriate sequence of these two
medication needs to be emphasized [21]. Conversely, if
the patient truly has a decreased aspirin response, then an
additional anti-platelet agent may be warranted. How-
ever, our data suggest that the preponderant cause of poor
platelet inhibition with aspirin is non-compliance and
that the clinician should be encouraged to work to
increase the patient's compliance with the prescribed
daily aspirin.
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